Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC)
Status:
Active, not recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
A recent investigation showed that a substantial proportion of patients with SQCLC (46%)
exhibit tumor overexpression of fibroblast growth factor receptor (FGFR) messenger
ribonucleic acid (mRNA) and are potentially sensitive to FGFR-targeting treatment.
Rogaratinib is a novel pan-FGFR inhibitor which showed strong anti-tumor efficacy in
pre-clinical models as a single agent in FGFR pathway-addicted tumor models. SQCLC patients
overexpressing tumor FGFR mRNA, who will be included into this clinical trial, do not have
currently any alternative systemic treatment with a proven and clinically reasonable benefit.
The objective of the trial is to determine clinical activity and safety of rogaratinib in
patients with advanced SQCLC overexpressing tumor FGFR1-3 mRNA.